Bristol Myers Squibb Company
NEWS
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look.
Bristol-Myers Squibb is looking to start 2020 on the right foot by filing a New Drug Application for its acute myeloid leukemia treatment CC-486 after data shows the medication extends survival time for AML patients.
As the 61st American Society of Hematology Annual Meeting wrapped up in Orlando, Florida, there were hundreds of studies and results presented. Here’s a look at some.
To help kick off the holiday season, BioSpace gave this Christmas classic a unique biopharma spin.
When Bristol-Myers Squibb acquired Celgene this year for $74 billion, one of the drugs it picked up was a CAR-T therapy, lisocabtagene maraleucel (liso-cel).
As usual, it was a busy week for clinical trial updates. Here’s a look.
With the acquisition complete, Celgene is now a wholly-owned subsidiary of BMS. The combined companies have nine products with more than $1 billion in annual sales.
The drug combination did not hit the co-primary endpoint of recurrence-free survival in patients whose tumors expressed PD-L1 greater than 1%.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
JOBS
IN THE PRESS